Literature DB >> 19225731

[Varenicline - pharmacological therapy of tobacco dependence].

Patricia Tschabitscher1, Irmgard Homaier, Alfred Lichtenschopf, Ernest Groman.   

Abstract

Every year about 1.2 million deaths attributable to smoking occur in Europe. Effective smoking cessation, therefore, is essential. Varenicline is the first medication specifically developed for smoking cessation. The efficacy of varenicline in smoking cessation is due to its role as a partial agonist/antagonist at the alpha4beta2 nicotine receptors. This dual action causes a reduction in cigarette craving as well as withdrawal symptoms; moreover, it decreases the pleasurable and reinforcing effects of smoking. This article discusses the current clinical data regarding efficacy and safety of varenicline and its role in smoking cessation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225731     DOI: 10.1007/s10354-008-0636-6

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  19 in total

1.  Effects of smoking cessation on blood pressure and heart rate variability in habitual smokers.

Authors:  J Minami; T Ishimitsu; H Matsuoka
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

2.  Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.

Authors:  J Cromwell; W J Bartosch; M C Fiore; V Hasselblad; T Baker
Journal:  JAMA       Date:  1997-12-03       Impact factor: 56.272

Review 3.  New treatments for smoking cessation.

Authors:  J R Hughes
Journal:  CA Cancer J Clin       Date:  2000 May-Jun       Impact factor: 508.702

4.  Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.

Authors:  Douglas E Jorenby; J Taylor Hays; Nancy A Rigotti; Salomon Azoulay; Eric J Watsky; Kathryn E Williams; Clare B Billing; Jason Gong; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

5.  Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

Authors:  David Gonzales; Stephen I Rennard; Mitchell Nides; Cheryl Oncken; Salomon Azoulay; Clare B Billing; Eric J Watsky; Jason Gong; Kathryn E Williams; Karen R Reeves
Journal:  JAMA       Date:  2006-07-05       Impact factor: 56.272

6.  Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.

Authors:  Jotham W Coe; Paige R Brooks; Michael G Vetelino; Michael C Wirtz; Eric P Arnold; Jianhua Huang; Steven B Sands; Thomas I Davis; Lorraine A Lebel; Carol B Fox; Alka Shrikhande; James H Heym; Eric Schaeffer; Hans Rollema; Yi Lu; Robert S Mansbach; Leslie K Chambers; Charles C Rovetti; David W Schulz; F David Tingley; Brian T O'Neill
Journal:  J Med Chem       Date:  2005-05-19       Impact factor: 7.446

Review 7.  Cellular mechanisms of nicotine addiction.

Authors:  J A Dani; M De Biasi
Journal:  Pharmacol Biochem Behav       Date:  2001-12       Impact factor: 3.533

8.  Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.

Authors:  Cheryl Oncken; David Gonzales; Mitchell Nides; Stephen Rennard; Eric Watsky; Clare B Billing; Richard Anziano; Karen Reeves
Journal:  Arch Intern Med       Date:  2006 Aug 14-28

9.  Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.

Authors:  R Scott Obach; Anne E Reed-Hagen; Suzanne S Krueger; Beth J Obach; Thomas N O'Connell; Kathleen S Zandi; Sandra Miller; Jotham W Coe
Journal:  Drug Metab Dispos       Date:  2005-10-12       Impact factor: 3.922

10.  Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.

Authors:  John A Stapleton; Lucy Watson; Lucy I Spirling; Robert Smith; Andrea Milbrandt; Marina Ratcliffe; Gay Sutherland
Journal:  Addiction       Date:  2007-11-19       Impact factor: 6.526

View more
  2 in total

1.  [Smoking].

Authors:  Michael Kunze; Ernest Groman
Journal:  Wien Med Wochenschr       Date:  2009

Review 2.  [The Fetal Tobacco Syndrome - A statement of the Austrian Societies for General- and Family Medicine (ÖGAM), Gynecology and Obstetrics (ÖGGG), Hygiene, Microbiology and Preventive Medicine (ÖGHMP), Pediatrics and Adolescence Medicine (ÖGKJ) as well as Pneumology (ÖGP)].

Authors:  Fritz Horak; Tamas Fazekas; Angela Zacharasiewicz; Ernst Eber; Herbert Kiss; Alfred Lichtenschopf; Manfred Neuberger; Rudolf Schmitzberger; Burkhard Simma; Andree Wilhelm-Mitteräcker; Josef Riedler
Journal:  Wien Klin Wochenschr       Date:  2011-12-22       Impact factor: 1.704

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.